| Filed On | Filing |
|---|---|
| 24 Sep 2024 |
8-K/A: Financial Statements and Exhibits
We have acted as special Nevada counsel to BioVie Inc., a Nevada corporation (the “Company”), in connection with the issuance and sale by the Company of (a) up to 1,360,800 shares (the “Shares”) of the Company’s Class A common stock, par... |
| 06 Aug 2024 |
8-K/A: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year
To the extent required by Item 3.03 of Form 8-K, the information regarding the Reverse Stock Split contained in Item 5.03 of this Current Report on Form 8-K/A is incorporated by reference herein. |
| 04 Mar 2024 |
8-K/A: Financial Statements and Exhibits
We have acted as special Nevada counsel to BioVie Inc., a Nevada corporation (the “Company”), in connection with the issuance and sale by the Company of (a) up to 15,000,000 shares (the “Shares”) of the Company’s Class A common stock, pa... |
| 07 Sep 2022 |
8-K/A: Regulation FD Disclosure; Other Events
Vast majority of patients saw significant improvements in the Global Rating of Change (overall impression of patient’s daily abilities) with NE3107 treatment (p<0.0001 to p<0.05). |
| 18 Jul 2022 |
8-K/A: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
This Securities Purchase Agreement (this “Agreement”) is dated as of July 15, 2022, between BioVie Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors an... |
| 30 May 2018 | 8-K/A: Creation of a Direct Financial Obligation |
| 29 Mar 2017 | 8-K/A: Departure/Election of Directors or Officers; Compensation |
Loading...
